Irampanel
 | |
| Systematic (IUPAC) name | |
|---|---|
|
N,N-Dimethyl-2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]ethanamine | |
| Identifiers | |
| CAS Number | 206260-33-5 |
| ATC code | None |
| PubChem | CID 3038472 |
| ChemSpider | 2302037 |
| ChEMBL | CHEMBL29741 |
| Chemical data | |
| Formula | C18H19N3O2 |
| Molar mass | 309.362 g/mol |
| |
| |
Irampanel (INN, code name BIIR-561) is a drug which acts as a dual noncompetitive antagonist of the AMPA receptor and neuronal voltage-gated sodium channel blocker.[1][2] It was under development by Boehringer Ingelheim for the treatment of acute stroke/cerebral ischemia but never completed clinical trials for this indication.[3][4] Irampanel was also trialed, originally, for the treatment of epilepsy and pain, but these indications, too, were abandoned,[1] and the drug was ultimately never marketed.
See also
References
- 1 2 Feigin V (June 2002). "Irampanel Boehringer Ingelheim". Curr Opin Investig Drugs 3 (6): 908–10. PMID 12137411.
- ↑ Wang KK, Larner SF, Robinson G, Hayes RL (December 2006). "Neuroprotection targets after traumatic brain injury". Curr. Opin. Neurol. 19 (6): 514–9. doi:10.1097/WCO.0b013e3280102b10. PMID 17102687.
- ↑ Arunabha Ray, Kavita Gulati (1 January 2007). Current Trends in Pharmacology. I. K. International Pvt Ltd. pp. 321–. ISBN 978-81-88237-77-7.
- ↑ Weiser T (April 2005). "AMPA receptor antagonists for the treatment of stroke". Curr Drug Targets CNS Neurol Disord 4 (2): 153–9. PMID 15857300.
| ||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Wednesday, December 16, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.